Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
Inspire Medical Systems, Inc. officer John Rondoni reported a tax-related share disposition. On February 13, 2026, the company withheld 587 shares of common stock at $59.76 per share to cover taxes due on the vesting of a restricted stock unit award. After this withholding, Rondoni directly owned 12,883 common shares. This was a tax-withholding transaction, not an open-market sale.
Inspire Medical Systems, Inc. officer Jason P. Kelly reported a tax-related share disposition. On February 13, 2026, 551 shares of common stock were withheld by the company at $59.76 per share to satisfy taxes upon vesting of a restricted stock unit award. After this withholding, Kelly directly holds 3,990 shares of Inspire Medical Systems common stock.
Inspire Medical Systems, Inc. officer Carlton Weatherby reported a Form 4 showing a tax-withholding disposition of company stock. On February 13, 2026, 570 shares of common stock were withheld at $59.76 per share to cover taxes due upon vesting of a restricted stock unit award. After this withholding, Weatherby directly owned 6,560 common shares, indicating the transaction was for tax purposes rather than an open-market sale.
Inspire Medical Systems, Inc. reported that officer Bryan K. Phillips had 579 shares of common stock withheld on a tax-withholding disposition related to the vesting of a restricted stock unit award. The shares were valued at $59.76 each, leaving him with 12,491 directly held shares afterward.
Inspire Medical Systems, Inc. received an updated ownership report from several Citadel-affiliated entities and Kenneth Griffin. The group may be deemed to beneficially own up to 527,217 Shares of Inspire Medical common stock, representing 1.8% of the Shares outstanding as of October 29, 2025.
Individual entities report smaller portions, such as Citadel Advisors–affiliated entities at 174,644 Shares (0.6%) and Citadel Securities LLC at 155,467 Shares (0.5%). The filers certify the securities are not held for the purpose of changing or influencing control of Inspire Medical.
Inspire Medical Systems describes its business built around Inspire, a fully implantable, closed-loop neurostimulation system for moderate to severe obstructive sleep apnea (OSA). The device gently stimulates the hypoglossal nerve during sleep to keep the airway open and is implanted in a 30‑ to 90‑minute outpatient procedure, with a battery designed to last about 11 years.
The company highlights extensive clinical evidence, including its pivotal STAR trial showing about a 70% median reduction in apnea‑hypopnea index from 29.3 to 9.0 events per hour at 12 months and sustained benefit to five years, and real‑world ADHERE registry data where patients used therapy 5.7 hours per night with 90% satisfaction and 92% willing to choose the procedure again. More than 125,000 patients have been treated across the U.S., Europe, and Asia.
Inspire sells primarily to hospitals and ambulatory surgery centers through a direct sales force, with 295 U.S. sales territories and 21 outside the U.S. It emphasizes broad insurance coverage, including positive policies from all large national commercial payors covering over 300 million U.S. lives, Medicare coverage through all seven MACs, and contracts with the Veterans Health Administration.
Inspire Medical Systems officer Carlton Weatherby, Chief Strategy and Growth Officer, reported a tax-withholding disposition of 327 shares of common stock on February 9, 2026 at $66.33 per share. After this transaction, Weatherby directly owned 7,130 shares of Inspire Medical Systems common stock.
Phillips Bryan K reported disposition transactions in a Form 4 filing for INSP. The filing lists transactions totaling 327 shares at a weighted average price of $66.33 per share. Following the reported transactions, holdings were 13,070 shares.
Herbert Timothy P. reported disposition transactions in a Form 4 filing for INSP. The filing lists transactions totaling 968 shares at a weighted average price of $66.33 per share. Following the reported transactions, holdings were 34,321 shares.
Inspire Medical Systems, Inc. executive John Rondoni, the Chief Product and Innovation Officer, reported a tax-related share disposition. On February 9, 2026, 327 shares of common stock were withheld by the company at $66.33 per share to cover taxes on a vested restricted stock unit award. After this withholding, Rondoni directly beneficially owned 13,470 common shares.